Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion-Reference-Cited by-同舟云学术

Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion

Published:2008-07-16 Issue:12 Volume:23 Page:3874-3879
ISSN:0931-0509
Container-title:Nephrology Dialysis Transplantation
language:en
Short-container-title:Nephrology Dialysis Transplantation

Author:

Calado J.,Sznajer Y.,Metzger D.,Rita A.,Hogan M. C.,Kattamis A.,Scharf M.,Tasic V.,Greil J.,Brinkert F.,Kemper M. J.,Santer R.

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ndt/article-pdf/23/12/3874/5330883/gfn386.pdf

Reference25 articles.

1. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

2. Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

3. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting

4. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse events and drug–drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure;Expert Review of Cardiovascular Therapy;2023-11-02

2. Genetic and clinical characterization of familial renal glucosuria;Clinical Kidney Journal;2023-10-17

3. Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2-inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose;Cardiovascular Research;2023-07-30

4. Performance of the ACMG‐AMP criteria in a large familial renal glucosuria cohort with identified SLC5A2 sequence variants;Clinical Genetics;2023-06-22

5. The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes;Pharmaceutics;2023-04-27